Abstract Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for patients with diabetes, obesity, and cardiometabolic disease. This trend has led to a growing number of patients taking these medications while receiving cancer treatment, including radiation therapy (RT).
The dramatic spike in glucagon-like peptide-1 (GLP-1) receptor agonist use is increasingly relevant to oncologists for various reasons, including a possible reduction in cancer risk and a potential role in survivorship care. I havent prescribed [GLP-1s], and I would say the majority of my colleagues would agree that they are not prescribing these drugs, but I do see a lot of patients on ...
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been reported to decrease cancer incidence, but less is known about their potential in patients with active cancer. Preclinical studies have demonstrated that GLP-1RAs inhibit progression of solid tumor malignancies via downregulation of cellular proliferation pathways and improved glycemic control. Despite these promising findings ...
Observational studies have suggested that glucagon-like peptide-1 receptor agonists medications (GLP-1 RA) may reduce the risk of heart failure and MACE compared with other antidiabetic agents, including metformin, among patients with T2D undergoing cancer-directed therapy [5], [6].
GLP-1 agonist medications work by mimicking this hormone. In medication terms, an agonist is a manufactured substance that attaches to a cell receptor and causes the same action as the naturally occurring substance.
